Seventh Sense Biosystems appoints new CEO, closes $10m Series A financing

Seventh Sense Biosystems, a privately held medical device company based in Cambridge, said Wednesday that Howard Weisman has been appointed president and chief executive and added that it has closed the final tranche of a $10 million Series A financing.

The financing was with existing investors Flagship Ventures and Polaris Venture Partners, the company said in a press release.

Founded in 2008, Seventh Sense is developing an array of products based on its proprietary painless blood collection platform.


The company said it will use the financing to complete clinical testing and to commercialize its first blood collection device for point of care diagnostics.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

Weisman was most recently the founder, chairman, and chief executive of EKR Therapeutics Inc., which announced its sale to Cornerstone Therapeutics in May.

According to its website, New Jersey-based EKR Therapeutics is a specialty pharmaceutical company that makes products that hospitals use for acute-care patients.

Chris Reidy can be reached at